Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/178676
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Klotz, Laurence | - |
dc.contributor.author | Pavlovich, Christian P. | - |
dc.contributor.author | Chin, Joseph | - |
dc.contributor.author | Hatiboglu, Gencay | - |
dc.contributor.author | Koch, Michael | - |
dc.contributor.author | Penson, David | - |
dc.contributor.author | Raman, Steven | - |
dc.contributor.author | Oto, Aytekin | - |
dc.contributor.author | Fütterer, Jurgen | - |
dc.contributor.author | Serrallach, Marc | - |
dc.contributor.author | Relle, James | - |
dc.contributor.author | Lotan, Yair | - |
dc.contributor.author | Heidenreich, Axel | - |
dc.contributor.author | Bonekamp, David | - |
dc.contributor.author | Haider, Masoom | - |
dc.contributor.author | Tirkes, Temel | - |
dc.contributor.author | Arora, Sandeep | - |
dc.contributor.author | Macura, Katarzyna J. | - |
dc.contributor.author | Costa, Daniel N. | - |
dc.contributor.author | Persigehl, Thorsten | - |
dc.contributor.author | Pantuck, Allan J. | - |
dc.contributor.author | Bomers, Joyce | - |
dc.contributor.author | Burtnyk, Mathieu | - |
dc.contributor.author | Staruch, Robert | - |
dc.contributor.author | Eggener, Scott | - |
dc.date.accessioned | 2021-06-25T11:07:39Z | - |
dc.date.available | 2021-06-25T11:07:39Z | - |
dc.date.issued | 2021-03-01 | - |
dc.identifier.uri | http://hdl.handle.net/2445/178676 | - |
dc.description.abstract | Purpose: Magnetic resonance imaging-guided transurethral ultrasound ablation uses directional thermal ultrasound under magnetic resonance imaging thermometry feedback control for prostatic ablation. We report 12-month outcomes from a prospective multicenter trial (TACT). Materials and methods: A total of 115 men with favorable to intermediate risk prostate cancer across 13 centers were treated with whole gland ablation sparing the urethra and apical sphincter. The co-primary 12-month endpoints were safety and efficacy. Results: In all, 72 (63%) had grade group 2 and 77 (67%) had NCCN® intermediate risk disease. Median treatment delivery time was 51 minutes with 98% (IQR 95-99) thermal coverage of target volume and spatial ablation precision of ±1.4 mm on magnetic resonance imaging thermometry. Grade 3 adverse events occurred in 9 (8%) men. The primary endpoint (U.S. Food and Drug Administration mandated) of prostate specific antigen reduction ≥75% was achieved in 110 of 115 (96%) with median prostate specific antigen reduction of 95% and nadir of 0.34 ng/ml. Median prostate volume decreased from 37 to 3 cc. Among 68 men with pretreatment grade group 2 disease, 52 (79%) were free of grade group 2 disease on 12-month biopsy. Of 111 men with 12-month biopsy data, 72 (65%) had no evidence of cancer. Erections (International Index of Erectile Function question 2 score 2 or greater) were maintained/regained in 69 of 92 (75%). Multivariate predictors of persistent grade group 2 at 12 months included intraprostatic calcifications at screening, suboptimal magnetic resonance imaging thermal coverage of target volume and a PI-RADS™ 3 or greater lesion at 12-month magnetic resonance imaging (p <0.05). Conclusions: The TACT study of magnetic resonance imaging-guided transurethral ultrasound whole gland ablation in men with localized prostate cancer demonstrated effective tissue ablation and prostate specific antigen reduction with low rates of toxicity and residual disease. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Wolters Kluwer Health | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1097/JU.0000000000001362 | - |
dc.relation.ispartof | Journal of Urology, 2021, vol. 205, num. 3, p. 769-779 | - |
dc.relation.uri | https://doi.org/10.1097/JU.0000000000001362 | - |
dc.rights | cc by-nc-nd (c) Klotz et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer de pròstata | - |
dc.subject.classification | Radioteràpia | - |
dc.subject.other | Prostate cancer | - |
dc.subject.other | Radiotherapy | - |
dc.subject.other | Imatges per ressonància magnètica | - |
dc.subject.other | Magnetic resonance imaging | - |
dc.title | Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-06-25T07:47:16Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33021440 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
JU.0000000000001362.pdf | 979.8 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License